制酸剤市場レポート：薬剤クラス別、製剤タイプ別、流通チャネル別、地域別、2025年～2033年

世界の制酸剤市場規模は2024年に72億米ドルに達しました。今後、IMARC Groupでは、2033年には97億米ドルに達し、2025～2033年の成長率（CAGR）は3.4％になると予測しています。市場が成長を遂げている主な理由は、小売薬局の拡大、OTC医薬品への嗜好、胃食道逆流症（GERD）患者数の増加が市場の成長を後押ししているためです。

制酸剤市場分析：

主な市場促進要因：制酸剤の需要を刺激しているのは、GERDに苦しむ人々が世界中で増加していることです。これは市場成長を促進する重要な要因の一つです。

主な市場動向：スイカミント、フルーティーシリアル、ストロベリーミルクシェイクなど、主要企業によるフレーバー付きチュアブルタイプの制酸剤の発売は、制酸剤市場の収益にプラスの影響を与えています。

地理的動向：アジア太平洋地域は制酸剤の最大地域市場です。これは、ヘルスケア支出の増加、高齢化、ヘルスケアセクターの拡大によるものです。

課題と機会：制酸剤市場における課題は、酸逆流に対する代替治療の存在であり、一方、機会は新興市場と消化器系問題を治療する革新的な製剤にあります。

制酸剤市場の動向：

胃食道逆流症（GERD）の影響

• 2022年の国立医学図書館の報告書によると、2019年には7億8,395万人がGERDの影響を受けています。GERDの苦しみを経験する人が増えれば増えるほど、制酸剤の需要を牽引しています。酸味に対する最良の治療は、そのいくつかの特質から制酸剤であると考えられています。制酸剤が即効性のある治療法であることは多くの人に知られており、制酸剤へのアクセスが容易であることも、制酸剤市場の成長に貢献しています。

高齢人口の増加による人口動態の変化

高齢者は、酸味から素早く解放される制酸剤の重要性を理解しています。その結果、これらの消化器系の問題を管理するために、制酸剤の常用消費者や購入者が増えています。高齢化率が高い国ほど、世界的に制酸剤の売上が高いと言えるかもしれません。2022年の世界保健機関（WHO）の報告によると、2030年、2050年には6人に1人が60歳以上になると言われています。60歳以上の世界人口も2020年の14億人から21億人に達します。

入手のしやすさから市販薬（OTC）への依存が高まる

処方箋のない治療薬は、軽い症状を治すために世界中で非常に好まれており、これが制酸剤の需要を喚起しています。制酸剤は薬局、食料品店、オンラインプラットフォームで簡単に入手でき、その結果、セルフメディケーションの目的で重要な役割を果たしています。制酸剤が提供する費用対効果や時間の節約といった利点は、現代人に非常に適したものとなっています。IMARC Groupの調査レポートによると、市販薬（OTC）の世界市場は2032年までに2,759億米ドルに達する見込みです。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の制酸剤市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：薬剤クラス別

• プロトンポンプ阻害剤
• H2拮抗薬
• 酸中和剤
• 運動促進剤

第7章 市場内訳：製剤タイプ別

• 錠剤
• 液体
• 粉
• その他

第8章 市場内訳：流通チャネル別

• 病院薬局
• 小売薬局
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場内訳：国別

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

List of Figures

• Figure 1: Global: Antacids Market: Major Drivers and Challenges
• Figure 2: Global: Antacids Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Antacids Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Antacids Market: Breakup by Drug Class (in %), 2024
• Figure 5: Global: Antacids Market: Breakup by Formulation Type (in %), 2024
• Figure 6: Global: Antacids Market: Breakup by Distribution Channel (in %), 2024
• Figure 7: Global: Antacids Market: Breakup by Region (in %), 2024
• Figure 8: Global: Antacids (Proton Pump Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Antacids (Proton Pump Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Antacids (H2 Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Antacids (H2 Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Antacids (Acid Neutralizers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Antacids (Acid Neutralizers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Antacids (Pro-Motility Agents) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Antacids (Pro-Motility Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Antacids (Tablet) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Antacids (Tablet) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Antacids (Liquid) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Antacids (Liquid) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Antacids (Powder) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Antacids (Powder) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Antacids (Other Formulation Types) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Antacids (Other Formulation Types) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Antacids (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Antacids (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Antacids (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Antacids (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Antacids (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Antacids (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: North America: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: North America: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: United States: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: United States: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Canada: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Canada: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Asia-Pacific: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Asia-Pacific: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: China: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: China: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Japan: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Japan: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: India: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: India: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: South Korea: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: South Korea: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Australia: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Australia: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Indonesia: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Indonesia: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Others: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Others: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Europe: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Europe: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Germany: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Germany: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: France: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: France: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: United Kingdom: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: United Kingdom: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Italy: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Italy: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Spain: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Spain: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Russia: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Russia: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Others: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Others: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Latin America: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Latin America: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Brazil: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Brazil: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Mexico: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Mexico: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Others: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Others: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Middle East and Africa: Antacids Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Middle East and Africa: Antacids Market: Breakup by Country (in %), 2024
• Figure 78: Middle East and Africa: Antacids Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 79: Global: Antacids Industry: SWOT Analysis
• Figure 80: Global: Antacids Industry: Value Chain Analysis
• Figure 81: Global: Antacids Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Antacids Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Antacids Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Global: Antacids Market Forecast: Breakup by Formulation Type (in Million USD), 2025-2033
• Table 4: Global: Antacids Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 5: Global: Antacids Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Antacids Market: Competitive Structure
• Table 7: Global: Antacids Market: Key Players

The global antacids market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033. The market is experiencing growth mainly because of the expansion of retail pharmacies, preference for OTC drugs, and rising number of patients experiencing gastroesophageal reflux disease (GERD) are impelling the growth of the market.

Antacids Market Analysis:

Major Market Drivers: People suffering from GERD is increasing around the world, which is catalyzing the demand for antacids. This represents one of the key factors propelling the market growth.

Key Market Trends: The launch of flavored and chewable antacids drugs by key players like watermelon mint, fruity cereals, and strawberry milkshake is positively impacting the antacids market revenue.

Geographical Trends: Asia Pacific is the largest regional market for antacids because of the rising healthcare expenditure, aging population, and healthcare sector expansion.

Key Players: Some of the major market players in the antacids industry include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., among many others.

Challenges and Opportunities: Challenges in the antacids market are the presence of alternative treatment for acid reflux, while opportunities lie in emerging markets and innovative formulations to treat digestive issues.

Antacids Market Trends:

Gastroesophageal reflux disease's (GERD) impact

• 783.95 million people were impacted by GERD in 2019 claimed by the report of the National Library of Medicine 2022. The more people going through the suffering of GERD, the more it is driving the demand for antacids. The best treatment for acidity is thought to be antacids because of their several qualities. Individuals are aware about the quick relief provided by antacids and their easy accessibility is further contributing to the antacids market growth.

Changing demographics because of rising geriatric population

Elderly people are understanding the importance of antacids because of their quick relief qualities from acidity. They are, as a result, a regular consumer or buyer of antacids to manage these digestive issues. It may be said that nations with increased aging population rates can have higher sales of antacids worldwide. As claimed by the World Health Organization's (WHO) report of 2022, 1 individual out of 6 will be of 60 years in age or over by 2030 and by 2050. The global population of those aged 60 and over will also reach 2.1 billion, up from 1.4 billion in 2020.

Rising reliance on over the counter (OTC) medicines due to their ease of availability

Non-prescribed remedies are highly preferred in the world to cure mild symptoms, which is catalyzing the antacids demand. Antacids are easily available via pharmacies, grocery stores, and online platforms and as a result play a crucial role in self-medication purposes. The cost-effectiveness and time saving benefits provided by antacids are making them highly suitable for people nowadays. The IMARC Group's research report mentions that the global market for over the counter (OTC) drugs will reach US$ 275.9 Billion by 2032.

Antacids Market Segmentation:

Breakup by Drug Class:

• Proton Pump Inhibitors
• H2 Antagonist
• Acid Neutralizers
• Pro-Motility Agents

Proton pump inhibitors accounts for the majority of the market share

Proton pump inhibitors are so effective and reliable that everyone wants them to cut down on stomach acid and indigestion. Healthcare professionals prescribed them as per the severity of acid reflux, leading to their higher sales. Key players are expanding their market as they know people are gaining knowledge about the positive impact of proton pump inhibitors in the body. For instance, Daewon Pharmaceutical introduced its first proton pump inhibitor medicine in Korea in 2022, known as Escorten.

Breakup by Formulation Type:

• Tablet
• Liquid
• Powder
• Others

Tablet holds the largest share of the industry

Easy storage, transportation, and administration are some benefits provided by tablets make them highly preferable among individuals. Tablets are hassle-free, as they can be easily consumed with water anywhere or on the go. Whether at office, home, or travel, people can get quick relief from acidity or indigestion through tablet drugs. The extended shelf life of tablets is viewed as another benefit compared to liquid or powder formulation type. Various tablets formulations present in the antacids market like chewable, delayed release, and effervescent are further creating a strong consumer base.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Retail pharmacies represent the leading market segment

In the first place, cities, suburbs, and rural areas all have numerous retail pharmacies around the world. Antacids as OTC drugs are highly popular & retail pharmacies are a significant outlet to purchase antacids. Secondly, the inclusion of a wide variety of antacids drugs in retail pharmacies can cater to several patients according to their preferences and demands. Thirdly, the focus of leading competitors in the retail pharmacy market on acquisition & expansion to increase their reach. The acquisition of Pharmaca by Medly Pharmacy in 2021 to deliver 360-degrees pharmacy services is one such example.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Asia Pacific leads the market, accounting for the largest antacids market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific enjoys the leading position in the market.

The densely populated countries like India and China are the largest markets for antacids in this region, as these countries are undergoing lifestyle shifts and Western food habits, which generally results in acid reflux and indigestion. Moreover, aging population in the region is viewed as an antacids market recent opportunities due to their high susceptibility to digestive issues. In line with this, lots of key players are present in the Asia Pacific region that are highly competitive and focus on partnerships and acquisition to expand their market. This was done by Dr. Reddy's Laboratories, a pharma company in India, when it acquired MenoLabs from Amyris Inc. in 2024 to cater to the evolving needs of people in the Asia Pacific region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major antacids companies have also been provided. Some of the major market players in the antacids industry include:

• Abbott Laboratories
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Pfizer Inc.
• Procter & Gamble Company
• Reckitt Benckiser Group PLC
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited.

(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)

The development of new formulations and product variants is done by key players through research and development (R&D) activities. They are introducing antacid drugs with flavors such as Fruity Cereal to meet the evolving demands of consumers. Top companies are taking advantage of elevated awareness about gastrointestinal health among people in developing countries. They are also eyeing on acquiring small businesses in the market while creating opportunities via antacids market recent developments. Using the digital health solutions is the main help method, enabling them to provide better health results. One such example was presented by AstraZeneca in November 2023, which it launched Evinova, a health-tech business, to offer advanced digital health solutions.

Key Questions Answered in This Report

• 1.How big is the antacids market?
• 2.What is the expected growth rate of the global antacids market during 2025-2033?
• 3.What are the key factors driving the global antacids market?
• 4.What has been the impact of COVID-19 on the global antacids market?
• 5.What is the breakup of the global antacids market based on the drug class?
• 6.What is the breakup of the global antacids market based on the formulation type?
• 7.What is the breakup of the global antacids market based on the distribution channel?
• 8.What are the key regions in the global antacids market?
• 9.Who are the key players/companies in the global antacids market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Antacids Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Proton Pump Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 H2 Antagonist
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Acid Neutralizers
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Pro-Motility Agents
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Formulation Type

• 7.1 Tablet
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Liquid
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Powder
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AstraZeneca plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bayer AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Boehringer Ingelheim International GmbH
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Dr. Reddy's Laboratories Ltd.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 GlaxoSmithKline plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Johnson & Johnson
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Procter & Gamble Company
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Reckitt Benckiser Group PLC
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Sanofi S.A.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Sun Pharmaceutical Industries Ltd.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Takeda Pharmaceutical Company Limited
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis